WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

Search

Hims & Hers Health Inc

Slēgts

SektorsPatēriņa aizsardzības

27.92 -10.34

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

27.74

Max

29.8

Galvenie mērījumi

By Trading Economics

Ienākumi

-50M

26M

Pārdošana

80M

481M

P/E

Sektora vidējais

54.722

44.466

EPS

0.227

Peļņas marža

5.409

Darbinieki

1,637

EBITDA

-8.2M

19M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+49.76% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-4.7B

6.5B

Iepriekšējā atvēršanas cena

38.26

Iepriekšējā slēgšanas cena

27.92

Ziņu noskaņojums

By Acuity

18%

82%

9 / 152 Rangs Consumer defensive

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Hims & Hers Health Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. apr. 23:15 UTC

Galvenie tirgus virzītāji

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025. g. 25. febr. 15:33 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

2024. g. 18. nov. 19:07 UTC

Galvenie tirgus virzītāji

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

2024. g. 14. okt. 15:02 UTC

Galvenie tirgus virzītāji

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

2024. g. 3. okt. 11:28 UTC

Galvenie tirgus virzītāji

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2025. g. 2. apr. 16:53 UTC

Top Ziņas

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

2025. g. 19. marts 15:54 UTC

Top Ziņas

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

2025. g. 21. febr. 23:20 UTC

Peļņas

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

2025. g. 10. febr. 12:00 UTC

Top Ziņas

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

2024. g. 19. dec. 17:16 UTC

Top Ziņas

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

2024. g. 19. dec. 15:14 UTC

Top Ziņas

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

2024. g. 19. dec. 15:02 UTC

Top Ziņas

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

2024. g. 16. dec. 13:47 UTC

Top Ziņas

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

2024. g. 16. dec. 07:00 UTC

Top Ziņas

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

2024. g. 3. okt. 14:45 UTC

Top Ziņas

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

2024. g. 3. okt. 13:12 UTC

Top Ziņas

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

2024. g. 3. okt. 11:45 UTC

Top Ziņas

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

2024. g. 3. okt. 10:14 UTC

Top Ziņas

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2024. g. 2. aug. 17:52 UTC

Iegādes, apvienošanās, pārņemšana

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

2024. g. 26. jūn. 11:00 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

2024. g. 24. maijs 20:37 UTC

Peļņas

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Salīdzinājums

Cenas izmaiņa

Hims & Hers Health Inc Prognoze

Cenas mērķis

By TipRanks

49.76% augšup

Prognoze 12 mēnešiem

Vidējais 46.5 USD  49.76%

Augstākais 85 USD

Zemākais 21 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Hims & Hers Health Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

13 ratings

5

Pirkt

6

Turēt

2

Pārdot

Tehniskais rādītājs

By Trading Central

31.0237 / 31.88Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

9 / 152 Rangs Patēriņa aizsardzības

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.